期刊文献+

用于肿瘤联合治疗的基因和化疗药物纳米共载体系的研究进展

Research progress in co-delivery of gene and chemotherapy drugs with nanocarriers for combination cancer therapy
原文传递
导出
摘要 化学药物治疗(化疗)或基因治疗单独使用治疗肿瘤均具有较多缺陷,而将两者联合应用能协同治疗肿瘤,克服单一疗法的不足.纳米载体既能包载化疗药物又能递送基因,其用于肿瘤的联合治疗,可减少化疗药物的剂量,增加药物在靶器官的分布量,减轻毒副作用,从而提高抗肿瘤效果;同时保护携带基因的稳定性和完整性,一定程度上提高基因的转染效率,以达到减轻毒副作用及提高疗效的协同目的.基因和化疗药物纳米共载体系用于肿瘤的联合治疗是近年来肿瘤治疗的研究热点.就基因和化疗药物纳米共载体系的类型及负载基因类型,特别是纳米共载体系用于肿瘤联合治疗的研究进行总结和展望. Chemotherapy or gene therapy has many defects when used alone in the treatment of cancers.Co-delivery of chemotherapy drugs and gene therapy could achieve synergistic therapeutic effect and overcome the shortcomings of monotherapy.Nanocarrier can package chemotherapy drugs and deliver genes for combination cancer therapy,which will increase the amount of the drug distribution in target organ and reduce the toxic side effects,thus enhancing the treatment efficacy.Meanwhile,the nanocarrier can protect the stability and integrity of genes,and improve the efficiency of gene transfection to a certain extent,to achieve the purpose of reducing side effects and improving the synergetic effects of the therapy.Co-delivery of gene and chemotherapy drugs with nanocarriers for combination cancer therapy is currently the hotspot of tumor treatment.The types of co-delivery carriers for gene and chemotherapy drugs and loading genetic types are summarized as well.On the basis,future research prospect is discussed.
出处 《国际生物医学工程杂志》 CAS 2016年第5期309-313,共5页 International Journal of Biomedical Engineering
基金 国家自然科学基金(U1304819,81401519) 国家级大学生创新训练计划项目(201410472030)
关键词 纳米载体 基因 化疗药物 肿瘤治疗 Nanocarier Gene Chemotherapy drug Cancer therapy
  • 相关文献

参考文献3

二级参考文献63

  • 1赵光,叶玲,张瑾峰,王喆.生物材料聚酰胺-胺树状大分子合成及其体外细胞相容性评价[J].中国生物医学工程学报,2005,24(6):750-754. 被引量:4
  • 2FREDERICK CA,WILLIAMS LD,UGHETTO G,et al.Structural comparison of anticancer drug-DNA complexes:adriamycin and daunomycin[J].Biochemistry,1990,29(10):2538-2549.
  • 3NOHL H.Identification of the site of adriamycin-activation in the heart cell[J].Biochem Pharmacol,1988,37(13):2633-2637.
  • 4MOHAN P,RAPOPORT N.Doxorubicin as a molecular nanotheranostic agent:effect of doxorubicin encapsulation in micelles or nanoemulsions on the ultrasound-mediated intracellular delivery and nuclear trafficking[J].Mol Pharm,2010,7(6):1959-1973.
  • 5NIIDOME T,HUANG L.Gene therapy progress and prospects:nonviral vectors[J].Gene Ther,2002,9(24):1647-1652.
  • 6AHMED KA,DAVIS BJ,WILSON TM,et al.Progress in gene therapy for prostate cancer[J].Front Oncol,2012,2:172.
  • 7HAN M,LV Q,TANG XJ,et al.Overcoming drug resistance of MCF-7/ADR cells by altering intracellular distribution of doxorubicin via MVP knockdown with a novel si RNA polyamidoamine-hyaluronic acid complex[J].J Control Release,2012,163(2):136-144.
  • 8CHANG KANG H,BAE YH.Co-delivery of small interfering RNA and plasmid DNA using a polymeric vector incorporating endosomolytic oligomeric sulfonamide[J].Biomaterials,2011,32(21):4914-4924.
  • 9HUSSAIN M,BEALE G,HUGHES M,et al.Co-delivery of an antisense oligonucleotide and 5-fluorouracil using sustained release poly(lactide-co-glycolide)microsphere formulations for potential combination therapy in cancer[J].Int J Pharm,2002,234(1-2):129-138.
  • 10ZHANG X,COLLINS L,SAWYER GJ,et al.In vivo gene delivery via portal vein and bile duct to individual lobes of the rat liver using a polylysine-based nonviral DNA vector in combination with chloroquine[J].Hum Gene Ther,2001,12(18):2179-2190.

共引文献18

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部